Friday, February 14, 2020
Sirtex Medical , a leading manufacturer of targeted liver cancer therapies , today announced a partnership with MIM Software Inc., a leading global provider of practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuro-imaging and cardiac imaging. Under the terms of the agreement, Sirtex's specialist sales teams in the United States, Europe and other major global markets will offer the MIM SurePlan TM LiverY90 software in addition to the SIR-Spheres ® Y-90 resin microspheres from the company to improve treatment precision for patients with liver tumors.
MIM SurePlan LiverY90 offers time-saving agents and post-treatment dosimetry for interventional radiologists and nuclear medicine physicians who treat liver tumors with SIR-Spheres. With the software, doctors can quickly calculate the dose delivered by the microspheres, thereby improving treatment decisions and patient care. The technology also includes CT, PET, SPECT and MRI scans to deliver simultaneous mood, coverage, and absorbed dose results, allowing doctors to make informed decisions about the next steps to be taken more quickly.
In addition to a shared mission to provide doctors with the tools they need to treat cancer, Sirtex and MIM also share the commitment to provide patients with the best care during their treatment process.
"Given the overlapping of their technology and our SIR-Spheres product, Sirtex and MIM have a long history of working with clinical care teams," said Kevin Smith , Chief Executive Officer of Sirtex . "And now as partners, we will be able to combine our expertise and resources to provide an even higher level of support during the treatment of liver tumors. We are happy to see how doctors will benefit from this collaboration and how it will will ultimately improve the patient's treatment outcomes. "
"We are proud and excited to partner with Sirtex, especially as it will provide access to personalized dosimetry for a large number of patients worldwide," said Andrew Nelson , Chief Executive Officer of MIM Software Inc. "The treatment of liver tumors requires a multidisciplinary approach, so it is a natural evolution for companies like ours to work together to provide an even faster and higher level of support, as well as tools for treatment teams."
In the United States, the SIR-Spheres Y-90 resin microspheres have received the Premarket Approval (PMA) from the FDA and the product is enrolled for the treatment of non-resectable metastatic liver tumors of primary colorectal cancer in combination with intra-hepatic chemotherapy of the veins where floxuridine is used. SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumors in Australia, the European Union, Argentina, Brazil, Canada and various countries in Asia, such as India and Singapore .
